- Home
- RARE vs NWBI Comparison
RARE vs NWBI Comparison
Compare RARE & NWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RARE | NWBI |
|---|---|---|
| Founded | 2010 | 1896 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RARE | NWBI |
|---|---|---|
| Price | $14.84 | $14.92 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 8 |
| Target Price | ★ $28.05 | $16.57 |
| AVG Volume (30 Days) | ★ 5.9M | 851.0K |
| Earning Date | 11-03-2026 | 10-26-2026 |
| Dividend Yield | N/A | ★ 5.39% |
| EPS Growth | 7.31 | ★ 16.46 |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $13.37 | $10.94 |
| Revenue Next Year | $31.21 | $4.59 |
| P/E Ratio | ★ N/A | $21.02 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $12.73 | $11.25 |
| 52 Week High | $39.89 | $16.16 |
Technical Indicators
Market Signals| Indicator | RARE | NWBI |
|---|---|---|
| Relative Strength Index (RSI) | 37.44 | 31.26 |
| Support Level | $13.81 | $14.22 |
| Resistance Level | $16.12 | $15.71 |
| Average True Range (ATR) | 0.82 | 0.27 |
| MACD | 0.50 | -0.07 |
| Stochastic Oscillator | 73.45 | 3.54 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution, offering personal and commercial banking solutions, business services, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and Commercial Banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Commercial Banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.